Exclusive Summary

• Unique Complementary Mechanism: First-in-class 'exercise-mimic' non-incretin modulator, operating as an ideal synergistic combo partner for highly successful GLP-1 therapies rather than competing head-to-head.
• Breakthrough Lean-Preserving Weight Loss: Preclinical models confirm it outperforms Tirzepatide by delivering greater fat reduction combined with exceptional lean mass preservation (up to 68.6%), resolving the severe muscle-atrophy crisis triggered by current anti-obesity medications.
• Exceptionally Improved Tolerability and Compliance: Promotes significant weight normalization without disrupting food intake behavior or escalating aversive visceral symptoms like nausea. It essentially permits GLP-1 dose de-escalations while ensuring once-weekly administration limits patient burden.
• Untapped Multi-Billion Dollar Indications: Beyond sheer obesity, the asset unlocks immense blue-ocean demographic targets including Sarcopenic obesity, Heart failure (HFrEF), and MASH, intercepting the unmet needs of aging and cardiovascular deterioration.
• Premium License-Out / Partnership Value: Nearing IND application steps (IND-enabling), UB660 is an ultimate strategic necessity for MNCs hungry to differentiate their pipeline or future-proof existing incretin mega-blockbusters from patent cliffs and generic flaws.

Asset Materials

Contact Us for Full Materials